Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Clinical trial NCT02298933 · COMPLETED
Trial details
- NCT number
- NCT02298933
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-21
- Primary completion
- 2017-08-08
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.